ErbB receptors and signaling pathways in cancer

被引：771

作者：

Hynes, Nancy E. ^{[1
]}

MacDonald, Gwen ^{[1
]}

机构：

[1] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland

来源：

CURRENT OPINION IN CELL BIOLOGY | 2009年 / 21卷 / 02期

关键词：

GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CELL LUNG-CANCER; BREAST-CANCER; ACQUIRED-RESISTANCE; TRASTUZUMAB RESISTANCE; EGFR MUTATIONS; HIGH-FREQUENCY; PI3K PATHWAY; PIK3CA GENE;

D O I：

10.1016/j.ceb.2008.12.010

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The ErbB receptor tyrosine kinases play important roles in normal physiology and in cancer. Epidermal growth factor receptor (EGFR) and ErbB2 in particular are mutated in many epithelial tumors, and clinical studies suggest that they play roles in cancer development and progression. These receptors have been intensely studied, not only to understand the mechanisms underlying their oncogenic potential, but also to exploit them as therapeutic targets. ErbB receptors activate a multiplicity of intracellular pathways via their ability to interact with numerous signal transducers. Furthermore, there are now many ErbB-targeted inhibitors used in the clinic. In this review we will concentrate on breast tumors with ERBB2 gene amplification/receptor overexpression and non-small cell lung cancer (NSCLC) with activating EGFR mutations. We will discuss data showing the important role that the PI3K/Akt pathway plays, not only in cancer development, but also in response to targeted therapies. Finally, mechanisms contributing to resistance to ErbB-targeted therapeutics will also be discussed.

引用

页码：177 / 184

页数：8

共 65 条

[1] Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy [J].

Amit, Ido ;

Wides, Ron ;

Yarden, Yosef .

MOLECULAR SYSTEMS BIOLOGY, 2007, 3 (1)

[2] The PIK3CA gene is mutated with high frequency in human breast cancers [J].

Bachman, KE ;

Argani, P ;

Samuels, Y ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Konishi, H ;

Karakas, B ;

Blair, BG ;

Lin, C ;

Peters, BA ;

Velculescu, VE ;

Park, BH .

CANCER BIOLOGY & THERAPY, 2004, 3 (08) :772-775

[3] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[4] ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface [J].

Berger, MB ;

Mendrola, JM ;

Lemmon, MA .

FEBS LETTERS, 2004, 569 (1-3) :332-336

[5]

BERGER MS, 1988, CANCER RES, V48, P1238

[6] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[7] AKT1E17K in human solid tumours [J].

Bleeker, F. E. ;

Felicioni, L. ;

Buttitta, F. ;

Lamba, S. ;

Cardone, L. ;

Rodolfo, M. ;

Scarpa, A. ;

Leenstra, S. ;

Frattini, M. ;

Barbareschi, M. ;

Del Grammastro, M. ;

Sciarrotta, M. G. ;

Zanon, C. ;

Marchetti, A. ;

Bardelli, A. .

ONCOGENE, 2008, 27 (42) :5648-5650

[8] Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors [J].

Buck, Elizabeth ;

Eyzaguirre, Alexandra ;

Rosenfeld-Franklin, Maryland ;

Thomson, Stuart ;

Mulvihill, Mark ;

Barr, Sharon ;

Brown, Eric ;

O'Connor, Mathew ;

Yao, Yan ;

Pachter, Jonathan ;

Miglarese, Mark ;

Epstein, David ;

Iwata, Kenneth K. ;

Haley, John D. ;

Gibson, Neil W. ;

Ji, Qun-Sheng .

CANCER RESEARCH, 2008, 68 (20) :8322-8332

[9] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[10] Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors [J].

Chen, Franklin L. ;

Xia, Wenle ;

Spector, Neil L. .

CLINICAL CANCER RESEARCH, 2008, 14 (21) :6730-6734

← 1 2 3 4 5 6 7 →